BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fourzali K, Golpanian RS, Yosipovitch G. Emerging drugs for the treatment of chronic pruritic diseases. Expert Opin Emerg Drugs 2020;25:273-84. [PMID: 32715798 DOI: 10.1080/14728214.2020.1801632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines (Basel) 2021;9:303. [PMID: 33807098 DOI: 10.3390/vaccines9030303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Misery L. Development of tools for the evaluation of pruritus. Br J Dermatol 2021;185:478-9. [PMID: 34128225 DOI: 10.1111/bjd.20492] [Reference Citation Analysis]
3 Szöllősi AG, Oláh A, Lisztes E, Griger Z, Tóth BI. Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk. Front Pharmacol 2022;13:745658. [DOI: 10.3389/fphar.2022.745658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov 2021. [PMID: 34417579 DOI: 10.1038/s41573-021-00266-6] [Reference Citation Analysis]